Loading…
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-172M | $-166M | $-113M | -212.2% | - | 105.5% |
| 2024 | $0M | $-91M | $-81M | $-71M | -46.9% | - | 118.1% |
| 2023 | $0M | $-41M | $-37M | $-34M | -45.2% | - | 4.5% |
| 2022 | $0M | $-36M | $-35M | $-28M | -31.9% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 36.53 | 41.76 | 90.89 | 172.50 |
| Research And Development | - | 24.25 | 27.67 | 73.28 | 154.22 |
| Selling General And Administration | - | 12.28 | 14.09 | 17.61 | 18.27 |
| Total Expenses | - | 36.53 | 41.76 | 90.89 | 172.50 |
| Operating Income | - | -36.53 | -41.76 | -90.89 | -172.50 |
| Total Operating Income As Reported | - | -36.53 | -41.76 | -90.89 | -172.50 |
| EBITDA | - | -36.21 | -41.45 | -90.57 | -172.15 |
| Normalized EBITDA | - | -36.21 | -41.45 | -90.57 | -172.15 |
| EBIT | - | -36.53 | -41.76 | -90.89 | -172.50 |
| Other Non Operating Income Expenses | - | 1.17 | 4.81 | 10.29 | 6.82 |
| Other Income Expense | - | 1.17 | 4.81 | 10.29 | 6.82 |
| Pretax Income | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income From Continuing And Discontinued Operation | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income From Continuing Operation Net Minority Interest | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income Common Stockholders | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income Including Noncontrolling Interests | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Normalized Income | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Diluted NI Availto Com Stockholders | - | -35.35 | -36.95 | -80.60 | -165.67 |
| Basic Average Shares | - | 25.76 | 43.90 | 61.26 | 72.95 |
| Diluted Average Shares | - | 25.76 | 43.90 | 61.26 | 72.95 |
| Reconciled Depreciation | - | 0.32 | 0.31 | 0.32 | 0.35 |
| General And Administrative Expense | - | 12.28 | 14.09 | 17.61 | 18.27 |
| Other Gand A | - | 12.28 | 14.09 | 17.61 | 18.27 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc.this co. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Atea Pharmaceuticals, Inc. | AVIR | $354M | -2.23 | 1.28 | -57.5% | -1.43 |
| Greenwich LifeSciences, Inc. | GLSI | $347M | -21.99 | 136.99 | -623.1% | - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM | $339M |
| - |
| - |
| - |
| - |
| -1.62 |
| 5.93 |
| -366.2% |
| -1.07 |
| Simulations Plus, Inc. | SLP | $336M | -5.20 | 2.70 | -51.9% | 20.82 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Abeona Therapeutics Inc. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Peer Median | - | -3.20 | 3.98 | -92.0% | -1.43 | |